Treatment of acute promyelocytic leukemia for older patients

Thomas Prebet, Steven D. Gore

Research output: Contribution to journalArticle

Abstract

Acute promyelocytic leukemia (APL) represents a remarkable disease in which leukemogenesis is driven by the PML-RARα oncogene and for which targeted treatment with all-trans retinoic acid (ATRA)-based therapy allows substantial chance of cure. APL is seen in a small subset of older patients, with age representing one of the most important prognostic factors for outcome of treatment. Unlike other acute leukemias, the inferior outcomes for APL in older patients relates less to changes in disease biology and more to the increased toxicity of ATRA and the chemotherapy combination regimens used to induce hematologic and molecular responses. Risk-adapted strategies that use less-toxic agents, such as arsenic trioxide, allow treatment of older patients, with greater efficiency and better chances of cure.

Original languageEnglish (US)
Pages (from-to)337-342
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume9
Issue number3
StatePublished - Mar 1 2011

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Poisons
Combination Drug Therapy
Oncogenes
Leukemia
Therapeutics

Keywords

  • Acute promyelocytic leukemia
  • All-trans retinoic acid
  • Arsenic
  • Older patient

ASJC Scopus subject areas

  • Oncology

Cite this

Treatment of acute promyelocytic leukemia for older patients. / Prebet, Thomas; Gore, Steven D.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 9, No. 3, 01.03.2011, p. 337-342.

Research output: Contribution to journalArticle

@article{1c7b345baaf14e1495e71884d734c42b,
title = "Treatment of acute promyelocytic leukemia for older patients",
abstract = "Acute promyelocytic leukemia (APL) represents a remarkable disease in which leukemogenesis is driven by the PML-RARα oncogene and for which targeted treatment with all-trans retinoic acid (ATRA)-based therapy allows substantial chance of cure. APL is seen in a small subset of older patients, with age representing one of the most important prognostic factors for outcome of treatment. Unlike other acute leukemias, the inferior outcomes for APL in older patients relates less to changes in disease biology and more to the increased toxicity of ATRA and the chemotherapy combination regimens used to induce hematologic and molecular responses. Risk-adapted strategies that use less-toxic agents, such as arsenic trioxide, allow treatment of older patients, with greater efficiency and better chances of cure.",
keywords = "Acute promyelocytic leukemia, All-trans retinoic acid, Arsenic, Older patient",
author = "Thomas Prebet and Gore, {Steven D.}",
year = "2011",
month = "3",
day = "1",
language = "English (US)",
volume = "9",
pages = "337--342",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "3",

}

TY - JOUR

T1 - Treatment of acute promyelocytic leukemia for older patients

AU - Prebet, Thomas

AU - Gore, Steven D.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Acute promyelocytic leukemia (APL) represents a remarkable disease in which leukemogenesis is driven by the PML-RARα oncogene and for which targeted treatment with all-trans retinoic acid (ATRA)-based therapy allows substantial chance of cure. APL is seen in a small subset of older patients, with age representing one of the most important prognostic factors for outcome of treatment. Unlike other acute leukemias, the inferior outcomes for APL in older patients relates less to changes in disease biology and more to the increased toxicity of ATRA and the chemotherapy combination regimens used to induce hematologic and molecular responses. Risk-adapted strategies that use less-toxic agents, such as arsenic trioxide, allow treatment of older patients, with greater efficiency and better chances of cure.

AB - Acute promyelocytic leukemia (APL) represents a remarkable disease in which leukemogenesis is driven by the PML-RARα oncogene and for which targeted treatment with all-trans retinoic acid (ATRA)-based therapy allows substantial chance of cure. APL is seen in a small subset of older patients, with age representing one of the most important prognostic factors for outcome of treatment. Unlike other acute leukemias, the inferior outcomes for APL in older patients relates less to changes in disease biology and more to the increased toxicity of ATRA and the chemotherapy combination regimens used to induce hematologic and molecular responses. Risk-adapted strategies that use less-toxic agents, such as arsenic trioxide, allow treatment of older patients, with greater efficiency and better chances of cure.

KW - Acute promyelocytic leukemia

KW - All-trans retinoic acid

KW - Arsenic

KW - Older patient

UR - http://www.scopus.com/inward/record.url?scp=79952662470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952662470&partnerID=8YFLogxK

M3 - Article

C2 - 21393443

AN - SCOPUS:79952662470

VL - 9

SP - 337

EP - 342

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 3

ER -